{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:22Z","timestamp":1792511602006,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ctrv.2012.02.002","type":"journal-article","created":{"date-parts":[[2012,2,26]],"date-time":"2012-02-26T03:51:11Z","timestamp":1330228271000},"page":"776-786","source":"Crossref","is-referenced-by-count":20,"title":["Antiresorptive therapies in oncology and their effects on cancer progression"],"prefix":"10.1016","volume":"38","author":[{"given":"Nigel","family":"Bundred","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.02.002_b0005","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2012.02.002_b0010","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.breast.2006.01.005","article-title":"Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program","volume":"15","author":"Aapro","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2012.02.002_b0015","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0020","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0025","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2012.02.002_b0030","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","article-title":"Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update","volume":"33","author":"Brufsky","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jocd.2006.07.005","article-title":"Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy","volume":"9","author":"Bruder","year":"2006","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ctrv.2012.02.002_b0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2012.02.002_b0045","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2007.10.005","article-title":"Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer","volume":"34","author":"Hadji","year":"2007","journal-title":"Semin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2012.02.002_b0050","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.02.002_b0055","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.002_b0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bone.2009.10.019","article-title":"The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial","volume":"46","author":"van Londen","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2012.02.002_b0070","first-page":"101","article-title":"Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy","volume":"7","author":"Swenson","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1185\/03007995.2010.535511","article-title":"Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis","volume":"27","author":"Hatoum","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ctrv.2012.02.002_b0080","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0085","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0090","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0095","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0100","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","article-title":"Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"182","author":"Smith","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.002_b0110","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2012.02.002_b0120","first-page":"9","article-title":"Bone health in men with prostate cancer: diagnostic and therapeutic considerations","volume":"12","author":"Saad","year":"2005","journal-title":"Can J Urol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0125","unstructured":"Prolia [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2010."},{"key":"10.1016\/j.ctrv.2012.02.002_b0130","unstructured":"Prolia (denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc. <http:\/\/pi.amgen.com\/united_states\/prolia\/prolia_pi.pdf>; 2011."},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2012.02.002_b0135","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/er.19.1.18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2012.02.002_b0145","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0150","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.02.002_b0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0160","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0165","unstructured":"Xgeva (denosumab) injection [package insert]. Thousand Oaks, CA: Amgen Inc.; 2010."},{"key":"10.1016\/j.ctrv.2012.02.002_b0170","unstructured":"Amgen Inc. Xgeva (denosumab) granted marketing authorization in the European Union [press release 2011]. <http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?releaseID=1585714>; 2011 [accessed 27.07.11]."},{"key":"10.1016\/j.ctrv.2012.02.002_b0175","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","article-title":"Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?","volume":"45","author":"Coleman","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0180","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/1078-0432.CCR-08-1572","article-title":"Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference","volume":"14","author":"Coleman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Avil\u00e9s","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0200","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.02.002_b0205","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2559.2007.02895.x","article-title":"Stem cells and breast cancer","volume":"52","author":"Cariati","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2012.02.002_b0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bone.2010.07.023","article-title":"Epithelial plasticity, cancer stem cells and bone metastasis formation","volume":"48","author":"van der Pluijm","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2012.02.002_b0225","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ar.1092270304","article-title":"Bone lining (endosteal) cells and hematopoiesis: a light microscopic study of normal and pathologic human bone marrow in plastic-embedded sections","volume":"227","author":"Islam","year":"1990","journal-title":"Anat Rec"},{"key":"10.1016\/j.ctrv.2012.02.002_b0230","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2008.48","article-title":"The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites","volume":"22","author":"Shiozawa","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2012.02.002_b0235","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.onc.1210768","article-title":"TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis","volume":"27","author":"Safina","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2012.02.002_b0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1101\/gad.1636908","article-title":"Migratory neighbors and distant invaders: tumor-associated niche cells","volume":"22","author":"Wels","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2012.02.002_b0245","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2012.02.002_b0250","first-page":"114s","article-title":"Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results","volume":"28","author":"Greenberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0255","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1186\/1471-2407-10-647","article-title":"Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells","volume":"10","author":"Raghu","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0260","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2012.02.002_b0265","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1074\/jbc.M707931200","article-title":"Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB","volume":"283","author":"Bhoopathi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.002_b0270","doi-asserted-by":"crossref","first-page":"30731","DOI":"10.1074\/jbc.M110.128124","article-title":"TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines","volume":"285","author":"Shin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.002_b0275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2007.11.032","article-title":"Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells","volume":"13","author":"Ahn","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2012.02.002_b0280","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2011.03.014","article-title":"Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo","author":"Franco","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0290","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2010.31.5069","article-title":"Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14","volume":"29","author":"Lipton","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.02.002_b0300","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","article-title":"Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway","volume":"65","author":"Bendre","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0305","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3109\/07357907.2010.512598","article-title":"Anticancer properties of zoledronic acid","volume":"28","author":"Green","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2012.02.002_b0310","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ijc.24756","article-title":"Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model","volume":"126","author":"Ottewell","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0315","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0320","first-page":"1351","article-title":"Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours","volume":"15","author":"Santini","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2012.02.002_b0325","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.02.002_b0330","first-page":"104","article-title":"Cancer immunotherapy: cytotoxic activity of {gamma}{delta} T-cells expanded ex vivo by the third generation bisphosphonate zoledronate","author":"Sato","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2012.02.002_b0335","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0340","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/BD-2007-26108","article-title":"Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis","volume":"26","author":"Allan","year":"2006","journal-title":"Breast Dis"},{"key":"10.1016\/j.ctrv.2012.02.002_b0345","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0350","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0355","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0360","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/bcr412","article-title":"Direct effects of bisphosphonates on breast cancer cells","volume":"4","author":"Senaratne","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0370","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CAD.0b013e3282f632bf","article-title":"Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth","volume":"19","author":"Monkkonen","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2012.02.002_b0375","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.canlet.2006.03.011","article-title":"Differential effects of bisphosphonates on breast cancer cell lines","volume":"246","author":"Verdijk","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2012.02.002_b0380","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0385","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2012.02.002_b0390","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","article-title":"Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt","volume":"278","author":"Bezzi","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.002_b0395","first-page":"2655","article-title":"Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro","volume":"25","author":"Muller","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0400","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0405","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2008.03.026","article-title":"Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation","volume":"43","author":"Guo","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2012.02.002_b0410","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/en.140.10.4451","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.02.002_b0415","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.002_b0420","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0425","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0430","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1515\/bc.2010.149","article-title":"Physiology and pathophysiology of the RANKL\/RANK system","volume":"391","author":"Hanada","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.002_b0435","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2012.02.002_b0440","doi-asserted-by":"crossref","first-page":"54841","DOI":"10.1074\/jbc.M406392200","article-title":"Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha","volume":"279","author":"Chaisson","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.002_b0445","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1043-2760(00)00351-9","article-title":"Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone","volume":"12","author":"Martin","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.002_b0450","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.002_b0455","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ydbio.2009.01.019","article-title":"The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse","volume":"328","author":"Fernandez-Valdivia","year":"2009","journal-title":"Dev Biol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0460","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.0915148107","article-title":"Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland","volume":"107","author":"Beleut","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.02.002_b0465","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/MCB.26.3.1002-1013.2006","article-title":"Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2","volume":"26","author":"Kim","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0470","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","article-title":"The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development","volume":"103","author":"Fata","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2012.02.002_b0475","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0306-9877(82)90018-4","article-title":"The role of 7, 12 DMBA and three hormones in 7, 12 DMBA-induced rat mammary cancer: three hypotheses","volume":"9","author":"Curtis","year":"1982","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ctrv.2012.02.002_b0480","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","article-title":"Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway","volume":"14","author":"Coscia","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0485","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL\u2013RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.002_b0490","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.002_b0495","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1128\/MCB.01298-06","article-title":"RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini","volume":"27","author":"Gonzalez-Suarez","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0500","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0505","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0510","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0515","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0520","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0525","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0530","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0535","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0540","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","article-title":"Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk","volume":"102","author":"Newcomb","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0545","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0550","doi-asserted-by":"crossref","unstructured":"Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and\/or tamoxifen or no therapy \u2013 final analysis [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6\u201310, 2011 [abstract S2\u20133].","DOI":"10.1158\/0008-5472.SABCS11-S2-3"},{"key":"10.1016\/j.ctrv.2012.02.002_b0555","doi-asserted-by":"crossref","unstructured":"M\u00f6bus V, Diel IJ, Harbeck N, et al. GAIN (German Adjuvant Intergroup Node Positive) study: a phase-III multicenter trial to compare dose dense, dose intense ETC. (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer \u2013 1st interim efficacy analysis [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6\u201310; 2011 [abstract S2\u20134].","DOI":"10.1158\/0008-5472.SABCS11-S2-4"},{"key":"10.1016\/j.ctrv.2012.02.002_b0560","doi-asserted-by":"crossref","unstructured":"de Boer R, Bundred N, Eidtmann H, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at: 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8\u201312; 2010 [abstract P5-11-01].","DOI":"10.1158\/0008-5472.SABCS10-P5-11-01"},{"key":"10.1016\/j.ctrv.2012.02.002_b0565","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2012.02.002_b0570","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0575","doi-asserted-by":"crossref","unstructured":"Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9\u201313; 2009 [abstract 4082].","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"key":"10.1016\/j.ctrv.2012.02.002_b0580","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0585","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0590","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0595","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancer [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6\u201310; 2011 [abstract S1\u20132].","DOI":"10.1158\/0008-5472.SABCS11-S1-2"},{"key":"10.1016\/j.ctrv.2012.02.002_b0600","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/annonc\/mdp200","article-title":"Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer","volume":"20","author":"Bidard","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2012.02.002_b0605","first-page":"20s","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2012.02.002_b0610","first-page":"170s","article-title":"Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients","volume":"69","author":"Solomayer","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0615","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0620","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2012.02.002_b0625","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm0806-875","article-title":"Is cancer a disease of self-seeding?","volume":"12","author":"Norton","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2012.02.002_b0630","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1477-7819-4-67","article-title":"Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells","volume":"4","author":"Camara","year":"2006","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0635","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0935-7","article-title":"Should bisphosphonates be utilized in the adjuvant setting for breast cancer?","volume":"122","author":"Lipton","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.002_b0640","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1872-034X.2010.00729.x","article-title":"Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma","volume":"40","author":"Katamura","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0645","article-title":"A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent\/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study","author":"Russell","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2012.02.002_b0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.02.002_b0655","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3727\/096504010X12671222663638","article-title":"Zoledronate stimulates gamma delta T cells in prostate cancer patients","volume":"18","author":"Naoe","year":"2010","journal-title":"Oncol Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0660","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0665","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ctrv.2012.02.002_b0670","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12032-008-9043-5","article-title":"Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases","volume":"25","author":"Tas","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0675","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2012.02.002_b0680","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0685","doi-asserted-by":"crossref","unstructured":"Winter MC, Syddall SP, Cross SS, et al. ANZAC: a randomised neoadjuvant biomarker study investigating the anti-tumour activity of the addition of zoledronic acid to chemotherapy in breast cancer. Presented at: the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8\u201312; 2010 [abstract P1-11-01].","DOI":"10.1158\/0008-5472.SABCS10-P1-11-01"},{"key":"10.1016\/j.ctrv.2012.02.002_b0690","unstructured":"Body J-J, Cook RJ, Costa L, et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at: IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, October 28\u201331; 2009 [poster 71]."},{"key":"10.1016\/j.ctrv.2012.02.002_b0695","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0700","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ctrv.2012.02.002_b0705","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2012.02.002_b0710","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.rdc.2006.07.004","article-title":"Inflammation-induced bone loss: can it be prevented?","volume":"32","author":"Romas","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ctrv.2012.02.002_b0715","unstructured":"US Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs. Denosumab. <http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM176595.pdf>; 2011 [accessed 14.03.11]."},{"key":"10.1016\/j.ctrv.2012.02.002_b0720","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2012.02.002_b0725","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","article-title":"Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab","volume":"21","author":"Toulis","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2012.02.002_b0730","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semarthrit.2011.03.005","article-title":"Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis","volume":"41","author":"von Keyserlingk","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2012.02.002_b0735","first-page":"343s","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer","volume":"28","author":"Fizazi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0740","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.002_b0745","doi-asserted-by":"crossref","unstructured":"Goss PE, Barrios CH, Bell R, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). Poster presented at: 2011 Annual ASCO Meeting, Chicago, IL, June 3\u20137; 2011 [abstract TPS152].","DOI":"10.1200\/jco.2011.29.15_suppl.tps152"},{"key":"10.1016\/j.ctrv.2012.02.002_b0750","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-011-1652-6","article-title":"Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?","author":"Bundred","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.002_b0755","unstructured":"Cancer Research UK. Breast cancer statistics\u2014key factors. <http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/breast\/>; 2011 [accessed 29.04.11]."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T04:09:08Z","timestamp":1640923748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":151,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0305737212000230"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}